Take­da spins PhII rare dis­ease pro­grams in­to new start­up — send­ing 2 ex­ecs and some cash to get things go­ing

The club of biotech star­tups de­vel­op­ing pro­grams spun out from Take­da keeps ad­mit­ting new mem­bers.

Oak Hill Bio is the lat­est to de­but, launch­ing not just with two Phase II rare dis­ease pro­grams but two Take­da ex­ecs who had di­rect ex­pe­ri­ence work­ing on those very drugs. The phar­ma gi­ant — which is grab­bing an up­front and an own­er­ship stake as well as mile­stones — al­so en­dowed the pipeline with four oth­er pre­clin­i­cal as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER